IntegraGen specializes in researching and identifying genetic biomarkers, primarily in the field of oncology. The group offers high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups. France accounts for 84.4% of net sales.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
26-09-14	€0.1230	-40.00%
26-09-11	€0.2050	-5.96%
26-09-10	€0.2180	-0.46%
26-09-09	€0.2190	-3.10%
26-09-08	€0.2260	+27.32%

Delayed Quote Börse Stuttgart

More quotes

Market Closed - Börse Stuttgart 15:56:05 2026-09-14 EDT			5-day change	1st Jan Change
0.1225 ^EUR	-40.24%		-30.79%	+53.12%

09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT

Market Cap	881K 1.02M 831K 753K 1.41M 97.17M 1.42M 9.92M 3.82M 49.42M 3.82M 3.73M 157M	P/E 2019	-23x	P/E 2020	-36.6x
Enterprise Value	-2.23M -2.57M -2.1M -1.91M -3.58M -246M -3.6M -25.11M -9.67M -125M -9.66M -9.45M -397M	EV / Sales 2019	0.49x	EV / Sales 2020	1.17x
Free-Float	32.13%	Yield 2019 *	-	Yield 2020	-

Markets		Quality
Euronext Paris	ALINT	Real-time
Börse Stuttgart	7N8	Delayed

09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT
06-16	IntegraGen Enters Receivership Proceedings
05-28	IntegraGen to file for court-ordered receivership
04-24	SSH Communications Security, Intragen Enter European Data Sovereignty Partnership	MT
04-23	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-10-30	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-02	IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025	CI
25-07-02	IntegraGen SA Reports Sales Results for the First Half of 2025	CI
25-04-29	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-15	IntegraGen SA Announces Unaudited Revenue Results for the Year 2024	CI
24-10-18	IntegraGen: losses reduced, share price soars
24-07-29	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI

IntegraGen Stock Börse Stuttgart

Stocks

7N8

FR0010908723

Biotechnology & Medical Research

Valuation: IntegraGen

Chart: IntegraGen

Latest news: IntegraGen

Press Releases: IntegraGen

News in other languages: IntegraGen

Quotes and Performance

Price Extremes

Managers and Directors: IntegraGen

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

25-07-02	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	PU
25-07-02	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	BU
25-04-29	IntegraGen: 2024 Annual Results	BU
25-01-15	IntegraGen : Inside Information / Information on annual revenues	PU
25-01-15	IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m	BU

09-14	Bourse : Capgemini vend sa division CGS, Euronext reparle consolidation et J&J pourrait céder son orthopédie
09-14	La love story du marché avec l'IA connaît quelques ratés
09-14	Deux offres de reprise déposées pour IntegraGen
09-11	IntegraGen annonce le dépôt de deux offres de reprise dans le cadre de son redressement judiciaire
06-16	Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime

1 day	-40.24%
1 week	-30.79%
Current month	-30.20%
1 month	-30.99%
3 months	-33.42%
6 months	-28.15%
Current year	+53.12%

1 week	0.12	0.23
1 month	0.12	0.23
Current year	0.1	0.33
1 year	0.07	0.33
3 years	0.07	1.32
5 years	0.07	1.46
10 years	0.07	1.46

Manager	Title	Age	Since
Bernard Courtieu CEO	Chief Executive Officer	62	2009-11-08
Virginie de Coster DFI	Director of Finance/CFO	-	2022-12-31
Berengere Genin COO	Chief Operating Officer	-	2023-12-31

Director	Title	Age	Since
Bernard Courtieu CHM	Chairman	62	2011-09-21
Jean-Pol Detiffe BRD	Director/Board Member	53	2020-12-31
François Blondel BRD	Director/Board Member	63	2023-12-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTEGRAGEN	-40.24%	-30.79%	-	-	1.53M
IOVANCE BIOTHERAPEUTICS, INC.	+7.67%	+5.35%	+307.93%	+70.38%	3.9B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+2.40%	+2.06%	+96.51%	+277.74%	3.86B
VERACYTE, INC.	+0.83%	-3.10%	+33.45%	+62.56%	3.29B
CAREDX, INC.	+4.20%	+2.93%	+287.07%	+523.45%	2.6B
BGI GENOMICS CO., LTD.	+2.37%	-0.38%	-33.13%	-30.48%	2.05B
FREENOME, INC.	-2.84%	-11.89%	+36.21%	-	1.54B
SEEGENE, INC.	+1.27%	+0.16%	+22.88%	+42.00%	1.07B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+2.37%	-8.67%	+150.37%	-33.68%	973M
CURIOX BIOSYSTEMS CO., LTD	-0.83%	-0.10%	-6.48%	+78.95%	616M
Average	-2.28%	-3.48%	+99.42%	+123.87%	2.21B
Weighted average by Cap.	+2.83%	-2.85%	+129.81%	+158.62%

	2019	2020
Net sales	8.28M 9.56M 7.81M 7.08M 13.29M 914M 13.39M 93.31M 35.95M 465M 35.89M 35.12M 1.48B	9M 10.39M 8.49M 7.7M 14.45M 993M 14.56M 101M 39.07M 505M 39.02M 38.17M 1.6B
Net income	-285K -329K -269K -244K -457K -31.43M -461K -3.21M -1.24M -15.99M -1.23M -1.21M -50.78M	-375K -433K -354K -321K -602K -41.38M -606K -4.23M -1.63M -21.05M -1.63M -1.59M -66.85M
Net Debt	-2.52M -2.91M -2.38M -2.15M -4.04M -278M -4.07M -28.38M -10.93M -141M -10.92M -10.68M -449M	-3.11M -3.59M -2.93M -2.66M -4.99M -343M -5.03M -35.04M -13.5M -174M -13.48M -13.19M -554M